Adipocytokines: A bridge connecting obesity and insulin resistance

Medical Hypotheses

Volumn 73, Issue 6, 2009, Pages 981-985

  Zhuang, Xiao Feng ^a   Zhao, Ming Ming ^b   Weng, Cui Lian ^a   Sun, Ning Ling ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; APELIN; FATTY ACID; GENE PRODUCT; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN;

ABDOMINAL OBESITY; ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; AUTOCRINE EFFECT; BODY FAT DISTRIBUTION; DISEASE ASSOCIATION; DISEASE COURSE; ENERGY EXPENDITURE; GLUCONEOGENESIS; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPID STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; SUBCUTANEOUS FAT; WEIGHT GAIN;

ADIPOKINES; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN RESISTANCE; OBESITY;

EID: 70449710851     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.05.036     Document Type: Article

References (41)

1. Banerji M.A., Faridi N., Atluri R., Chaiken R.L., and Lebovitz H.E. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 84 1 (1999) 137-144
2. Lin E., Phillips L.S., Ziegler T.R., et al. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes 56 3 (2007) 735-742
3. Marks S.J., Moore N.R., Clark M.L., Strauss B.J., and Hockaday T.D. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 4 1 (1996) 1-7
4. Bergman R.N., and Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11 9 (2000) 351-356
5. Trujillo M.E., and Scherer P.E. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27 7 (2006) 762-778
6. Wang J.L., Chinookoswong N., Scully S., Qi M., and Shi Z.Q. Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology 140 5 (1999) 2117-2124
7. Hamilton B.S., Paglia D., Kwan A.Y., and Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1 9 (1995) 953-956
8. Cnop M., Landchild M.J., Vidal J., et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51 4 (2002) 1005-1015
9. Bahceci M, Gokalp D, Bahceci S, et al. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest 2007;30(3):210-14.
10. Einstein F.H., Atzmon G., Yang X.M., et al. Differential responses of visceral and subcutaneous fat depots to nutrients. Diabetes 54 3 (2005) 672-678
11. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 8 (2001) 947-953
12. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 7 (2002) 731-737
13. Milan G., Granzotto M., Scarda A., et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 10 11 (2002) 1095-1103
14. Park H.S., Park J.Y., and Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 69 1 (2005) 29-35
15. Bogan J.S., and Lodish H.F. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol 146 3 (1999) 609-620
16. Smith U., Axelsen M., Carvalho E., et al. Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. Ann NY Acad Sci 892 (1999) 119-126
17. Cao Y.L., Hu C.Z., Meng X., Wang D.F., and Zhang J. Expression of TNF-alpha protein in omental and subcutaneous adipose tissue in obesity. Diabetes Res Clin Pract 79 2 (2008) 214-219
18. Winkler G., Kiss S., Keszthelyi L., et al. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol 149 2 (2003) 129-135
19. Nonogaki K., Fuller G.M., Fuentes N.L., et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136 5 (1995) 2143-2149
20. Curat C.A., Wegner V., Sengenes C., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49 4 (2006) 744-747
21. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 5708 (2005) 426-430
22. Choi K.C., Ryu O.H., Lee K.W., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 336 3 (2005) 747-753
23. Hector J., Schwarzloh B., Goehring J., et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 39 4 (2007) 250-255
24. Alessi M.C., Peiretti F., Morange P., et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46 5 (1997) 860-867
25. Shimomura I., Funahashi T., Takahashi M., et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2 7 (1996) 800-803
26. Yang R.Z., Lee M.J., Hu H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290 6 (2006) 1253-1261
27. SM O., Hansen M.J., Tatemoto K., and Morris M.J. Inhibitory effect of apelin-12 on nocturnal food intake in the rat. Nutr Neurosci 6 3 (2003) 163-167
28. Wei L., Hou X., and Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept 132 1-3 (2005) 27-32
29. Heinonen M.V., Purhonen A.K., Miettinen P., et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 130 1-2 (2005) 7-13
30. Hida K., Wada J., Eguchi J., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102 30 (2005) 10610-10615
31. Seeger J., Ziegelmeier M., Bachmann A., et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 93 1 (2008) 247-251
32. Suleymanoglu S, Tascilar E, Pirgon O, et al. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009.
33. Lundgren M., Buren J., Ruge T., Myrnas T., and Eriksson J.W. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 89 6 (2004) 2989-2997
34. Jensen M.D., Sarr M.G., Dumesic D.A., Southorn P.A., and Levine J.A. Regional uptake of meal fatty acids in humans. Am J Physiol Endocrinol Metab 285 6 (2003) 1282-1288
35. Kabir M., Catalano K.J., Ananthnarayan S., et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288 2 (2005) 454-461
36. Frayn K.N. Adipose tissue as a buffer for daily lipid flux. Diabetologia 45 9 (2002) 1201-1210
37. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10 4 (1990) 493-496
38. Williamson J.R. Mechanism for the stimulation in vivo of hepatic gluconeogenesis by glucagon. Biochem J 101 1 (1966) 11-14
39. Jensen MD. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 2006;14(Suppl. 1):20-4.
40. Ishikawa K., Takahashi K., Bujo H., et al. Subcutaneous fat modulates insulin sensitivity in mice by regulating TNF-alpha expression in visceral fat. Horm Metab Res 38 10 (2006) 631-638
41. Sewter C.P., Blows F., Vidal-puig A., and RS O. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 51 3 (2002) 718-723